Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses

Stock News

06/22

An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.

According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1117535956"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117535956\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117535956?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117535956","market":"us","top_or_hot":-1,"title":"Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses","media":"Stock News","content":"<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-06-22 11:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1117535956","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117535956","pubTimestamp":1782097579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药-U","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","BK0239":"医药制造","BK1191":"制药","01477":"欧康维视生物-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"泽璟生物制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"VXUS":1,"IPOS":1,"01477":1},"content_text":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}